110 related articles for article (PubMed ID: 3489037)
1. Molecular analysis of an HLA-A2 functional variant CLA defined by cytolytic T lymphocytes.
Ezquerra A; Doménech N; van der Poel J; Strominger JL; Vega MA; López de Castro JA
J Immunol; 1986 Sep; 137(5):1642-9. PubMed ID: 3489037
[TBL] [Abstract][Full Text] [Related]
2. Delineation of functional sites in HLA-B27 antigens. Molecular analysis of HLA-B27 variant Wewak I defined by cytolytic T lymphocytes.
Vega MA; Wallace L; Rojo S; Bragado R; Aparicio P; López de Castro JA
J Immunol; 1985 Nov; 135(5):3323-32. PubMed ID: 3930603
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of amino acid substitutions in the beta-sheet floor and alpha-2 helix of HLA-A2 on recognition by alloreactive viral peptide-specific cytotoxic T lymphocytes.
Mattson DH; Shimojo N; Cowan EP; Baskin JJ; Turner RV; Shvetsky BD; Coligan JE; Maloy WL; Biddison WE
J Immunol; 1989 Aug; 143(4):1101-7. PubMed ID: 2473117
[TBL] [Abstract][Full Text] [Related]
4. Comparative structural analysis of HLA-A3 antigens distinguishable by cytotoxic T lymphocytes: variant E1.
van Schravendijk MR; Biddison WE; Berger AE; Coligan JE
J Immunol; 1985 Jan; 134(1):410-6. PubMed ID: 3871112
[TBL] [Abstract][Full Text] [Related]
5. Clonal T lymphocyte recognition of the fine structure of the HLA-A2 molecule.
Brenner MB; McLean J; Yang SY; van der Poel JJ; Pious D; Strominger JL
J Immunol; 1985 Jul; 135(1):384-90. PubMed ID: 2582041
[TBL] [Abstract][Full Text] [Related]
6. Identification by site-directed mutagenesis of amino acid residues contributing to serologic and CTL-defined epitope differences between HLA-A2.1 and HLA-A2.3.
Hogan KT; Clayberger C; Bernhard EJ; Walk SF; Ridge JP; Parham P; Krensky AM; Engelhard VH
J Immunol; 1988 Oct; 141(7):2519-25. PubMed ID: 2459215
[TBL] [Abstract][Full Text] [Related]
7. A panel of unique HLA-A2 mutant molecules define epitopes recognized by HLA-A2-specific antibodies and cytotoxic T lymphocytes.
Hogan KT; Clayberger C; Bernhard EJ; Walk SF; Ridge JP; Parham P; Krensky AM; Engelhard VH
J Immunol; 1989 Mar; 142(6):2097-104. PubMed ID: 2466083
[TBL] [Abstract][Full Text] [Related]
8. Comparative structural analysis of HLA-A2 antigens distinguishable by cytotoxic T lymphocytes. II. Variant DK1: evidence for a discrete CTL recognition region.
Krangel MS; Biddison WE; Strominger JL
J Immunol; 1983 Apr; 130(4):1856-62. PubMed ID: 6601143
[TBL] [Abstract][Full Text] [Related]
9. Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line.
Ware CF; Krangel MS; Pious D; Burakoff SJ; Strominger JL
J Immunol; 1983 Sep; 131(3):1312-7. PubMed ID: 6193184
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the alpha 2 domain of HLA-A2.
Parham P; Clayberger C; Zorn SL; Ludwig DS; Schoolnik GK; Krensky AM
Nature; 1987 Feb 12-18; 325(6105):625-8. PubMed ID: 2433598
[TBL] [Abstract][Full Text] [Related]
11. Structural analysis of an HLA-B7 antigen variant detected by cytotoxic T lymphocytes.
Taketani S; Krangel MS; Spits H; de Vries J; Strominger JL
J Immunol; 1984 Aug; 133(2):816-21. PubMed ID: 6429245
[TBL] [Abstract][Full Text] [Related]
12. Structural identity between HLA-A2 antigens differentially recognized by alloreactive cytotoxic T lymphocytes.
Castaño AR; Lauzurica P; Domenech N; López de Castro JA
J Immunol; 1991 May; 146(9):2915-20. PubMed ID: 2016531
[TBL] [Abstract][Full Text] [Related]
13. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
14. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
Takahashi T; Irie RF; Nishinaka Y; Hoon DS
Clin Cancer Res; 1997 Aug; 3(8):1363-70. PubMed ID: 9815820
[TBL] [Abstract][Full Text] [Related]
15. Structural analysis of HLA-A2.4 functional variant KNE. Implications for the mapping of HLA-A2-specific T-cell epitopes.
Doménech N; Ezquerra A; Castaño R; López de Castro JA
Immunogenetics; 1988; 27(3):196-202. PubMed ID: 2448239
[TBL] [Abstract][Full Text] [Related]
16. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection.
Nayersina R; Fowler P; Guilhot S; Missale G; Cerny A; Schlicht HJ; Vitiello A; Chesnut R; Person JL; Redeker AG; Chisari FV
J Immunol; 1993 May; 150(10):4659-71. PubMed ID: 7683326
[TBL] [Abstract][Full Text] [Related]
17. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
18. One allogeneic cytolytic T lymphocyte clone distinguishes three different HLA-B27 subtypes: identification of amino acid residues influencing the specificity and avidity of recognition.
Aparicio P; Vega MA; López de Castro JA
J Immunol; 1985 Nov; 135(5):3074-81. PubMed ID: 2413111
[TBL] [Abstract][Full Text] [Related]
19. Molecular cloning and DNA sequence analysis of genes encoding cytotoxic T lymphocyte-defined HLA-A3 subtypes: the E1 subtype.
Cowan EP; Jordan BR; Coligan JE
J Immunol; 1985 Oct; 135(4):2835-41. PubMed ID: 2993417
[TBL] [Abstract][Full Text] [Related]
20. The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206.
Torikai H; Akatsuka Y; Miyauchi H; Terakura S; Onizuka M; Tsujimura K; Miyamura K; Morishima Y; Kodera Y; Kuzushima K; Takahashi T
Bone Marrow Transplant; 2007 Jul; 40(2):165-74. PubMed ID: 17530010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
